Patents by Inventor Shuichan Xu

Shuichan Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20180235960
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 23, 2018
    Inventors: Shuichan XU, Kristen Mae HEGE, Heather RAYMON, Rama K. NARLA, Rajesh CHOPRA
  • Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
    Patent number: 10004735
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 26, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Kimberly Elizabeth Fultz, Tam Minh Tran, Shuichan Xu, Weiming Xu
  • Treatment of cancer with dihydropyrazino-pyrazines
    Patent number: 9980963
    Abstract: Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: May 29, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Shuichan Xu, Antonia Lopez-Girona, Toshiya Tsuji, Kristen Mae Hege
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 9937170
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 10, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Antonia Lopez-Girona, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES
    Publication number: 20170312278
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.
    Type: Application
    Filed: July 20, 2017
    Publication date: November 2, 2017
    Inventors: Kimberly Elizabeth FULTZ, Tam Minh TRAN, Shuichan XU, Weiming XU
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9795607
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: October 24, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20170281633
    Abstract: Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 5, 2017
    Inventors: John F. Boylan, Gordon L. Bray, Ellen Filvaroff, Robert Hubbard, David Mikolon, Heather Raymon, Tao Shi, Tam M. Tran, Toshiya Tsuji, Lilly L. Wong, Shuichan Xu, Dan Zhu
  • Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
    Patent number: 9737535
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer, wherein the TOR kinase inhibitor is a compound of formula (I): and pharmaceutically acceptable salts, clathrates, solvates, stereoisomers, tautomers, metabolites, isotopologues and prodrugs thereof.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: August 22, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Kimberly Elizabeth Fultz, Tam Minh Tran, Shuichan Xu, Weiming Xu
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9737541
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: August 22, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • METHODS OF TREATING A CANCER USING SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF
    Publication number: 20170173024
    Abstract: Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
    Type: Application
    Filed: March 8, 2017
    Publication date: June 22, 2017
    Inventors: Dan ZHU, John BOYLAN, Shuichan XU, Jennifer RIGGS, Tao SHI, David MIKOLON, Gordafaried DEYANAT-YAZDI
  • Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
    Patent number: 9623028
    Abstract: Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 18, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Dan Zhu, John Boylan, Shuichan Xu, Jennifer Riggs, Tao Shi, Andrew Wurmser, David Mikolon, Gordafaried Deyanat-Yazdi
  • TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES
    Publication number: 20170065583
    Abstract: Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia.
    Type: Application
    Filed: October 21, 2016
    Publication date: March 9, 2017
    Inventors: HEATHER RAYMON, SHUICHAN XU, ANTONIA LOPEZ-GIRONA, TOSHIYA TSUJI, KRISTEN MAE HEGE
  • SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20170042902
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20170027932
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Application
    Filed: September 27, 2016
    Publication date: February 2, 2017
    Inventors: Shuichan XU, Kristen Mae HEGE, Antonia LOPEZ-GIRONA, Heather RAYMON, Rama K. NARLA, Rajesh CHOPRA
  • Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors
    Patent number: 9555033
    Abstract: Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: January 31, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Rajesh Chopra, Yuhong Ning, Sabita Sankar, Shuichan Xu, Weiming Xu
  • Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity
    Patent number: 9557338
    Abstract: Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3? or p70S6K1.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: January 31, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Weiming Xu, Deborah Mortensen, Shuichan Xu, Kimberly Elizabeth Fultz
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9512124
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: December 6, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao, John Frederick Boylan
  • Treatment of cancer with dihydropyrazino-pyrazines
    Patent number: 9505764
    Abstract: Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: November 29, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Shuichan Xu, Antonia Lopez-Girona, Toshiya Tsuji, Kristen Mae Hege
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 9493466
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 15, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Antonia Lopez-Girona, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20160324861
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 10, 2016
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu